The Atlantic   |  April 19, 2021

he United States is projected to have more than 300 million spare doses (not including those earmarked for most of the country’s children when they become eligible), according to the Duke Global Health Innovation Center. Allocating a small chunk of those doses to Americans overseas might seem reasonable. But exporting the U.S.’s vaccine success to citizens beyond its borders is “one bridge too far,” Lawrence Gostin, a health-policy expert and the director of the O’Neill Institute for National and Global Health Law at Georgetown University, told me.

Read more here.